HK1218930A1 - 新型多特異性結構 - Google Patents
新型多特異性結構Info
- Publication number
- HK1218930A1 HK1218930A1 HK16106937.5A HK16106937A HK1218930A1 HK 1218930 A1 HK1218930 A1 HK 1218930A1 HK 16106937 A HK16106937 A HK 16106937A HK 1218930 A1 HK1218930 A1 HK 1218930A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- multispecific constructs
- novel multispecific
- novel
- constructs
- multispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762755P | 2013-02-08 | 2013-02-08 | |
| PCT/US2014/015409 WO2014124326A1 (en) | 2013-02-08 | 2014-02-07 | Novel multispecific constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1218930A1 true HK1218930A1 (zh) | 2017-03-17 |
Family
ID=51300173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16106937.5A HK1218930A1 (zh) | 2013-02-08 | 2016-06-16 | 新型多特異性結構 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10047163B2 (zh) |
| EP (1) | EP2954056A4 (zh) |
| JP (1) | JP2016509014A (zh) |
| CA (1) | CA2900764A1 (zh) |
| HK (1) | HK1218930A1 (zh) |
| WO (1) | WO2014124326A1 (zh) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| KR102493430B1 (ko) | 2014-05-28 | 2023-01-31 | 자임워크스 비씨 인코포레이티드 | 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 |
| GB201414823D0 (en) | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
| CA2959045A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Washington | Wnt signaling agonist molecules |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MX375970B (es) | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| KR20180069839A (ko) | 2015-10-08 | 2018-06-25 | 자임워크스 인코포레이티드 | 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도 |
| WO2017117179A1 (en) | 2015-12-28 | 2017-07-06 | Massachusetts Institute Of Technology | Bispecific antibodies having constant region mutations and uses therefor |
| CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| ES2906639T3 (es) | 2016-03-25 | 2022-04-19 | Biomunex Pharmaceuticals | Moléculas de unión a CD38 y PD-L1 |
| CN109563166B (zh) | 2016-04-28 | 2022-12-20 | 拜奥穆尼克斯制药 | 靶向egfr和her2的双特异性抗体 |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| ES2975263T3 (es) | 2016-06-20 | 2024-07-04 | Novartis Ag | Formas cristalinas de un compuesto triazolopirimidínico |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| US12049511B2 (en) | 2016-11-10 | 2024-07-30 | Fortis Therapeutics, Inc. | Engineered CD46-specific effector cells and uses thereof in the treatment of cancer |
| CN110267685B (zh) | 2016-12-23 | 2023-06-20 | 伊缪诺金公司 | 靶向adam9的免疫缀合物及其使用方法 |
| US11242402B2 (en) | 2016-12-23 | 2022-02-08 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
| CA3053010A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| IL269559B2 (en) * | 2017-03-27 | 2024-06-01 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019051308A1 (en) * | 2017-09-07 | 2019-03-14 | Dragonfly Therapeutics, Inc. | NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR |
| WO2019126399A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| JP7330977B2 (ja) | 2017-12-19 | 2023-08-22 | スロゼン オペレーティング， インコーポレイテッド | Ｗｎｔサロゲート分子及びその使用 |
| CN111448217A (zh) * | 2017-12-22 | 2020-07-24 | 阿根思公司 | 双特异性抗原结合构建体 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| WO2019148410A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| KR20200132875A (ko) | 2018-02-20 | 2020-11-25 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| SG11202012257VA (en) | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN108997493B (zh) * | 2018-08-15 | 2019-07-09 | 中国农业科学院兰州兽医研究所 | 一种全牛源o型口蹄疫病毒广谱中和抗体的制备方法 |
| GB201820556D0 (en) * | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| CA3124796A1 (en) | 2018-12-24 | 2020-07-02 | Sanofi | Multispecific binding proteins with mutant fab domains |
| US20220089752A1 (en) * | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| CN114126714A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2020172571A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| CA3130508A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2021226193A1 (en) | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
| US11484604B2 (en) | 2020-08-07 | 2022-11-01 | Fortis Therapeutics, Inc. | Immunoconjugates targeting CD46 and methods of use thereof |
| CA3190573A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Methods of detecting trbc1 or trbc2 |
| EP4204096A4 (en) | 2020-08-26 | 2024-10-02 | Marengo Therapeutics, Inc. | ANTIBODY MOLECULES BINDING TO NKP30 AND USES THEREOF |
| JP2023542080A (ja) | 2020-08-26 | 2023-10-05 | マレンゴ・セラピューティクス，インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
| CN117729942A (zh) | 2021-03-08 | 2024-03-19 | 伊缪诺金公司 | 用于增加靶向adam9的免疫缀合物治疗癌症的功效的方法 |
| AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| JP5011277B2 (ja) | 2005-04-06 | 2012-08-29 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| JP2010538012A (ja) | 2007-08-28 | 2010-12-09 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | Ｉｇｆ−１ｒの複数のエピトープに結合する組成物 |
| US20090155255A1 (en) | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| ES2774337T3 (es) * | 2008-01-07 | 2020-07-20 | Amgen Inc | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| US9067986B2 (en) * | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| WO2011069104A2 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| US20130089554A1 (en) * | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| CN103313726B (zh) | 2010-09-03 | 2016-08-17 | 施特姆森特克斯股份有限公司 | 细胞亚群的鉴定和富集 |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| JP6083871B2 (ja) | 2010-09-29 | 2017-02-22 | アジェンシス，インコーポレイテッド | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| KR101973930B1 (ko) | 2010-11-05 | 2019-04-29 | 자임워크스 인코포레이티드 | Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인 |
| SG190990A1 (en) * | 2010-12-08 | 2013-07-31 | Stem Centrx Inc | Novel modulators and methods of use |
| WO2012162583A1 (en) | 2011-05-26 | 2012-11-29 | Ibc Pharmaceuticals, Inc. | Design and construction of novel multivalent antibodies |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| KR102398736B1 (ko) * | 2011-10-31 | 2022-05-16 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| ES2871418T3 (es) | 2013-08-28 | 2021-10-28 | Abbvie Stemcentrx Llc | Composiciones y métodos de conjugación de anticuerpos específicos de sitio |
| WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
-
2014
- 2014-02-07 JP JP2015557143A patent/JP2016509014A/ja active Pending
- 2014-02-07 CA CA2900764A patent/CA2900764A1/en not_active Abandoned
- 2014-02-07 US US14/765,861 patent/US10047163B2/en not_active Expired - Fee Related
- 2014-02-07 EP EP14749020.5A patent/EP2954056A4/en not_active Withdrawn
- 2014-02-07 WO PCT/US2014/015409 patent/WO2014124326A1/en active Application Filing
-
2016
- 2016-06-16 HK HK16106937.5A patent/HK1218930A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2954056A1 (en) | 2015-12-16 |
| JP2016509014A (ja) | 2016-03-24 |
| CA2900764A1 (en) | 2014-08-14 |
| WO2014124326A1 (en) | 2014-08-14 |
| US20150368352A1 (en) | 2015-12-24 |
| EP2954056A4 (en) | 2016-09-21 |
| US10047163B2 (en) | 2018-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218930A1 (zh) | 新型多特異性結構 | |
| HK1224312A1 (zh) | 新型化合物 | |
| IL246002A0 (en) | New methods | |
| GB201311910D0 (en) | Novel Compounds | |
| GB201311888D0 (en) | Novel compounds | |
| GB201317363D0 (en) | Novel compounds | |
| GB201518344D0 (en) | No details present | |
| HUE063222T2 (hu) | Fotobioreaktor | |
| EP2968338A4 (en) | NEW USES | |
| GB201318222D0 (en) | Novel compounds | |
| GB201314926D0 (en) | Novel Compounds | |
| GB201322512D0 (en) | Novel compounds | |
| HK1213566A1 (zh) | 新的四唑酮衍生物 | |
| GB201320021D0 (en) | Novel Compounds | |
| HK1218746A1 (zh) | 新穎化合物 | |
| GB201316762D0 (en) | Novel compounds | |
| GB201316764D0 (en) | Novel compounds | |
| GB201306308D0 (en) | Novel process | |
| GB201306192D0 (en) | Novel methods | |
| GB201401185D0 (en) | Novel compounds | |
| GB201321972D0 (en) | Novel compounds | |
| GB201321977D0 (en) | Novel compounds | |
| GB201321976D0 (en) | Novel compounds | |
| GB201321975D0 (en) | Novel compounds | |
| GB201321811D0 (en) | Novel compounds |